AACR26: Dr. Brian Wolpin on pancreatic cancer research | Dana-Farber Cancer Institute

An aspirational goal in pancreatic cancer treatment may be closer to reality, based on new clinical trial data from a study led by Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber. The presentation at AACR26 shows that a multi-selective RAS inhibitor daraxonrasib is active against the KRAS mutations most frequently seen in pancreatic cancer and can be taken as a daily pill, with initial data suggesting promising results either alone or with chemotherapy as a first-line treatment for metastatic pancreatic cancer. ➡️https://bit.ly/4cAoXMU Video published 4/23/2026